L

LSP

Description

LSP is a defense & space company that offers strategy consulting services.

Investor Profile

LSP has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 50% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B rounds (top funding stages).
  • Majority of deals are located in France, Belgium.
  • Strong thematic focus on Biotechnology, Health Care, Medical.

Stage Focus

  • Series A (50%)
  • Series B (50%)

Country Focus

  • France (50%)
  • Belgium (50%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Wellness
  • Medical Device
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does LSP frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 1
CA
Europe, Rhone-Alpes, France, Champagne-au-mont-d'or
Co-Investments: 1
Novo Ventures
Europe, Hovedstaden, Denmark, Bagsværd
Co-Investments: 1
Kurma Partners
Europe, Ile-de-France, France, Paris
Co-Investments: 1
EQT Life Sciences
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 1
Bpifrance
Europe, Ile-de-France, France, Maisons-alfort
Co-Investments: 1
Pontifax
Asia, Tel Aviv, Israel, Herzliya
Co-Investments: 1
Sham
Europe, Rhone-Alpes, France, Lyon
Co-Investments: 1
Partners Innovation Fund
North America, Massachusetts, United States, Boston
Co-Investments: 1
BNP Paribas Private Equity
Europe, Ile-de-France, France, Paris
Co-Investments: 1

What are some of recent deals done by LSP?

etherna immunotherapies

Niel, Antwerpen, Belgium

etherna develops mRNA and lipid nanoparticle solutions.

BiotechnologyHealth CareMedical DeviceTherapeutics
Series BJun 16, 2020
Amount Raised: $38,306,104
Amolyt Pharma

Écully, Rhone-Alpes, France

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

BiotechnologyHealth CareMedicalPharmaceuticalWellness
Series AJul 31, 2019
Amount Raised: $74,180,691